Internal Medicine, Medical Oncology · Palm Coast, FL
NPI
1013002880
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1 Memorial Medical Pkwy Ste 200
Palm Coast, FL, 32164
Phone (386) 586-1860
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.0M
636,432 services
Medicare patients, 2024
1,498
Average age 76
Drug cost, 2024
$11.2M
4,402 prescriptions
Company payments, 2025
$506
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Padmaja Sai was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 109,140 times for 85 patients. In total Padmaja Sai billed 636,432 services in 175 codes, and Medicare paid $9.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-17.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 109,140 | 85 | $0.28 | $30K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 32,032 | 18 | $0.06 | $1,778 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 31,600 | 26 | $44.73 | $1.4M |
| J0897 Injection, denosumab, 1 mg | Office | 30,660 | 234 | $20.43 | $627K |
| J0185 Injection, aprepitant, 1 mg | Office | 24,440 | 36 | $1.33 | $33K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 21,600 | 13 | $0.27 | $5,725 |
| J1756 Injection, iron sucrose, 1 mg | Office | 21,200 | 18 | $0.17 | $3,703 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 17,940 | 11 | $39.32 | $705K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 16,520 | 77 | $6.37 | $105K |
| J9267 Injection, paclitaxel, 1 mg | Office | 12,791 | 18 | $0.08 | $1,042 |
| Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg | Office | 8,703 | 16 | $50.89 | $443K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 7,333 | 94 | $0.09 | $663 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 6,600 | 54 | $16.10 | $106K |
| J1434 Injection, fosaprepitant (focinvez), 1 mg | Office | 6,600 | 19 | $2.34 | $15K |
| 36415 Venipuncture Blood Collection | Office | 5,814 | 1,300 | $8.65 | $50K |
By year: 2022 $8.5M for 705,801 services; 2023 $7.3M for 611,068 services; 2024 $9.0M for 636,432 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 5,814 | 1,300 | $8.65 | $50K |
| 85025 Blood Count | 5,194 | 1,157 | $7.60 | $39K |
| 85610 Clinical Chemistry | 293 | 26 | $4.20 | $1,231 |
| 81003 Clinical Chemistry | 198 | 37 | $2.20 | $436 |
| 85045 Blood Count | 72 | 65 | $3.91 | $282 |
Medicare prescription drug claims, 2024
In 2024, the drug Padmaja Sai prescribed most often to Medicare patients was Anastrozole, with 339 prescriptions and refills. In total Padmaja Sai wrote 4,402 Medicare prescriptions that cost $11.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 339 | 942 | 130 | $7,804 |
| Eliquis Apixaban | 258 | 408 | 82 | $230K |
| Prednisone Generic | 228 | 302 | 93 | $1,442 |
| Ondansetron Odt Ondansetron | 197 | 198 | 138 | $3,730 |
| Omeprazole Generic | 155 | 260 | 67 | $1,411 |
| Gabapentin Generic | 149 | 216 | 47 | $1,851 |
| Dexamethasone Generic | 141 | 160 | 59 | $3,998 |
| Hydroxyurea Generic | 134 | 330 | 39 | $3,671 |
| Allopurinol Generic | 95 | 144 | 24 | $1,006 |
| Acyclovir Generic | 95 | 153 | 29 | $1,240 |
| Imbruvica Ibrutinib | 89 | 89 | Under 11 | $1.4M |
| Revlimid Lenalidomide | 87 | 87 | 13 | $1.4M |
| Megestrol Acetate Generic | 79 | 89 | 48 | $5,807 |
| Levofloxacin Generic | 75 | 75 | 54 | $476 |
| Abiraterone Acetate Generic | 70 | 72 | Under 11 | $172K |
Brand drugs: 1,110 claims; generic drugs: 3,292 claims; opioid claims: 130.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Padmaja Sai $506 ($506 in general payments such as food, travel and fees) from 13 companies. The largest payer was Gilead Sciences, Inc. with $96.97.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 4 | $96.97 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $96.08 |
| GlaxoSmithKline, LLC. GSK | 3 | $57.93 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $54.55 |
| AstraZeneca Pharmaceuticals LP AZN | 1 | $33.48 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $31.44 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $25.92 |
| Pfizer Inc. PFE | 1 | $25.64 |
| Janssen Biotech, Inc. JNJ | 1 | $21.39 |
| Taiho Oncology, Inc. 4578.T | 1 | $18.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.